Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| VOLITIONRX LTDVNRX · Entity 8241 | Director · President and CEO | February 26, 2026 | February 27, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
VOLITIONRX LTD
Report date February 26, 2026 · Filed February 27, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 3,115,547 |
Reported balance
After 2026-02-26 transaction · row 1
1 source rowRow 1 · 2026-02-26 · Grant · Acquired 486,000 · Balance 3,115,547 F1: On February 26, 2026, the reporting person was awarded 486,000 restricted stock units ("RSUs") under the Issuer's 2024 Stock Incentive Plan in lieu of cash compensation that would otherwise have been owed to the reporting person. The RSUs will be earned in twelve approximately equal monthly installments commencing on March 1, 2026. Once earned, they will remain subject to additional time-based vesting in a single installment on February 26, 2027, and are generally subject to continued service by the reporting person throughout each applicable earning and vesting date. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of RSUs that have been earned and vested as of the vesting date. |
| Common StockSEC Table I · non-derivative | IndirectBy Concord International, Inc. | 1,007,718 |
Reported balance
Holding disclosure · report date 2026-02-26 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 1,007,718 F2: The shares of common stock are held directly by Concord International, Inc. Mr. Reynolds is the majority shareholder of Concord International, Inc. and shares voting and dispositive control over the shares of common stock held by Concord International, Inc. |
| Common StockSEC Table I · non-derivative | IndirectBy Spouse | 34,076 |
Reported balance
Holding disclosure · report date 2026-02-26 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 34,076 |
Filing footnotes · ownership attribution and instrument terms
F1: On February 26, 2026, the reporting person was awarded 486,000 restricted stock units ("RSUs") under the Issuer's 2024 Stock Incentive Plan in lieu of cash compensation that would otherwise have been owed to the reporting person. The RSUs will be earned in twelve approximately equal monthly installments commencing on March 1, 2026. Once earned, they will remain subject to additional time-based vesting in a single installment on February 26, 2027, and are generally subject to continued service by the reporting person throughout each applicable earning and vesting date. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of RSUs that have been earned and vested as of the vesting date.
F2: The shares of common stock are held directly by Concord International, Inc. Mr. Reynolds is the majority shareholder of Concord International, Inc. and shares voting and dispositive control over the shares of common stock held by Concord International, Inc.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 20, 2018 Filed Dec 21, 2018 22:32 UTC | VOLITIONRX LTD VNRX · Entity 8241 | GrantOption (Right to Buy) · Derivative | 55,000 | $0.00 Strike: $4.00 | $0.00 |
DisclosureSEC source: 0001078782-18-001452 · primary_doc.xml · derivative · entry 6 Reynolds Cameron John · CIK 0001340610 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,000 Underlying: Common Stock · 55,000 shares Expires 2021-07-23 F2 · kind: The reported transactions involved an amendment of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of "replacement" options. The "old" options were originally granted on July 23, 2015 and vested in full at 6 months from the date of grant, and were exercisable for four years from the date first exercisable. The "replacement" options are fully-vested and expire on July 23, 2021. Read SEC document |
| December 20, 2018 Filed Dec 21, 2018 22:32 UTC | VOLITIONRX LTD VNRX · Entity 8241 | Disposition to issuerOption (Right to Buy) · Derivative | 55,000 | $0.00 Strike: $4.00 | $0.00 |
DisclosureSEC source: 0001078782-18-001452 · primary_doc.xml · derivative · entry 5 Reynolds Cameron John · CIK 0001340610 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 55,000 shares Expires 2020-01-23 F2 · kind: The reported transactions involved an amendment of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of "replacement" options. The "old" options were originally granted on July 23, 2015 and vested in full at 6 months from the date of grant, and were exercisable for four years from the date first exercisable. The "replacement" options are fully-vested and expire on July 23, 2021. Read SEC document |
| December 20, 2018 Filed Dec 21, 2018 22:32 UTC | VOLITIONRX LTD VNRX · Entity 8241 | GrantOption (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $3.00 | $0.00 |
DisclosureSEC source: 0001078782-18-001452 · primary_doc.xml · derivative · entry 4 Reynolds Cameron John · CIK 0001340610 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2020-08-18 F1 · kind: The reported transactions involved an amendment of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of "replacement" options. The "old" options were originally granted on August 18, 2014 and vested in two equal installments at 6 months and at 18 months from the date of grant, and were exercisable for four years from the date first exercisable. The "replacement" options are fully-vested and both installments expire on August 18, 2020. Read SEC document |
| December 20, 2018 Filed Dec 21, 2018 22:32 UTC | VOLITIONRX LTD VNRX · Entity 8241 | GrantOption (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $2.50 | $0.00 |
DisclosureSEC source: 0001078782-18-001452 · primary_doc.xml · derivative · entry 3 Reynolds Cameron John · CIK 0001340610 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2020-08-18 F1 · kind: The reported transactions involved an amendment of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of "replacement" options. The "old" options were originally granted on August 18, 2014 and vested in two equal installments at 6 months and at 18 months from the date of grant, and were exercisable for four years from the date first exercisable. The "replacement" options are fully-vested and both installments expire on August 18, 2020. Read SEC document |
| December 20, 2018 Filed Dec 21, 2018 22:32 UTC | VOLITIONRX LTD VNRX · Entity 8241 | Disposition to issuerOption (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $3.00 | $0.00 |
DisclosureSEC source: 0001078782-18-001452 · primary_doc.xml · derivative · entry 2 Reynolds Cameron John · CIK 0001340610 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 50,000 shares Expires 2020-02-18 F1 · kind: The reported transactions involved an amendment of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of "replacement" options. The "old" options were originally granted on August 18, 2014 and vested in two equal installments at 6 months and at 18 months from the date of grant, and were exercisable for four years from the date first exercisable. The "replacement" options are fully-vested and both installments expire on August 18, 2020. Read SEC document |
| December 20, 2018 Filed Dec 21, 2018 22:32 UTC | VOLITIONRX LTD VNRX · Entity 8241 | Disposition to issuerOption (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $2.50 | $0.00 |
DisclosureSEC source: 0001078782-18-001452 · primary_doc.xml · derivative · entry 1 Reynolds Cameron John · CIK 0001340610 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 50,000 shares Expires 2019-02-18 F1 · kind: The reported transactions involved an amendment of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of "replacement" options. The "old" options were originally granted on August 18, 2014 and vested in two equal installments at 6 months and at 18 months from the date of grant, and were exercisable for four years from the date first exercisable. The "replacement" options are fully-vested and both installments expire on August 18, 2020. Read SEC document |
| August 16, 2018 Filed Aug 17, 2018 14:39 UTC | VOLITIONRX LTD VNRX · Entity 8241 | PurchaseCommon Stock | 6,500 | $1.91 | $12,415.00 |
DisclosureSEC source: 0001078782-18-000886 · primary_doc.xml · nonDerivative · entry 1 Reynolds Cameron John · CIK 0001340610 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,121,173 Read SEC document |
| January 23, 2018 Filed Jan 25, 2018 21:47 UTC | VOLITIONRX LTD VNRX · Entity 8241 | GrantStock Option (Right to Buy) · Derivative | 75,000 | $0.00 Strike: $4.00 | $0.00 |
DisclosureSEC source: 0001078782-18-000069 · primary_doc.xml · derivative · entry 1 Reynolds Cameron John · CIK 0001340610 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2024-01-23 F1 · derivative.exercise_date: A total of 75,000 Options were granted on January 23, 2018 under the Company's 2015 Stock Incentive Plan. The Options vest in full twelve months from the date of grant. Read SEC document |
| August 16, 2017 Filed Aug 17, 2017 20:08 UTC | VOLITIONRX LTD VNRX · Entity 8241 | PurchaseCommon Stock | 3,630 | $2.77 | $10,055.10 |
DisclosureSEC source: 0001078782-17-001160 · primary_doc.xml · nonDerivative · entry 1 Reynolds Cameron John · CIK 0001340610 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · Concord International, Inc. Disclosed balance after: 1,007,718 F1 · ownership.nature: The shares of Common Stock are held directly by Concord International, Inc. Mr. Reynolds is the majority shareholder of Concord International, Inc. and shares voting and dispositive control over the shares of Common Stock held by Concord International, Inc. Read SEC document |
| March 30, 2017 Filed Apr 3, 2017 20:27 UTC | VOLITIONRX LTD VNRX · Entity 8241 | GrantStock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $5.00 | $0.00 |
DisclosureSEC source: 0001078782-17-000411 · primary_doc.xml · derivative · entry 1 Reynolds Cameron John · CIK 0001340610 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2023-03-30 F1 · derivative.exercise_date: A total of 100,000 Options were granted on March 30, 2017 under the Company's 2015 Stock Incentive Plan. The Options vest in full twelve months from the date of grant. Read SEC document |
| November 18, 2016 Filed Nov 21, 2016 21:14 UTC | VOLITIONRX LTD VNRX · Entity 8241 | Exercise / conversionStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $3.00 | $0.00 |
DisclosureSEC source: 0001078782-16-003843 · primary_doc.xml · derivative · entry 3 Reynolds Cameron John · CIK 0001340610 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires 2016-11-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 18, 2016 Filed Nov 21, 2016 21:14 UTC | VOLITIONRX LTD VNRX · Entity 8241 | Tax withholdingCommon Stock | 13,393 | $4.48 | $60,000.64 |
DisclosureSEC source: 0001078782-16-003843 · primary_doc.xml · nonDerivative · entry 2 Reynolds Cameron John · CIK 0001340610 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,114,673 F1 · shares: Represents the aggregate number of shares of common stock retained by VolitionRx for cancellation as payment of the exercise price in a cashless exercise. No shares were sold by the Reporting Person or VolitionRx in such cashless exercise transaction. Read SEC document |
| November 18, 2016 Filed Nov 21, 2016 21:14 UTC | VOLITIONRX LTD VNRX · Entity 8241 | Exercise / conversionCommon Stock | 20,000 | $3.00 | $60,000.00 |
DisclosureSEC source: 0001078782-16-003843 · primary_doc.xml · nonDerivative · entry 1 Reynolds Cameron John · CIK 0001340610 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,128,066 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.